Extracorporeal shockwave therapy for intermittent claudication: Medium-term outcomes from a double-blind randomised placebo-controlled pilot trial

Abstract

Objectives

Peripheral arterial disease most commonly presents as intermittent claudication (IC). Early evidence has suggested that extracorporeal shockwave therapy is efficacious in the short term for the management of intermittent claudication. The objective of this pilot trial was to evaluate the medium-term efficacy of this treatment.

Methods

This double-blind randomised placebo-controlled pilot trial randomised patients with unilateral intermittent claudication in a 1:1 fashion to receive extracorporeal shockwave therapy or a sham treatment for three sessions per week over three weeks. Primary outcomes were maximum walking distance and intermittent claudication distance using a fixed-load treadmill test. Secondary outcomes included pre- and post-exertional ankle-brachial pressure indices, safety and quality of life assessed using generic (SF36, EQ-5D-3L) and disease-specific (vascular quality of life) measures. All outcome measures were assessed at 12 months post-treatment.

Results

Thirty participants were included in the study (extracorporeal shockwave therapy, n = 15; sham, n = 15), with 26 followed up and analysed at 12 months (extracorporeal shockwave therapy, n = 13; sham, n = 13). Intragroup analysis demonstrated significant improvements in maximum walking distance, intermittent claudication distance and post-exertional ankle-brachial pressure indices (p < 0.05) in the active treatment group, with no improvements in pre-exertional ankle-brachial pressure indices. Significant improvements in quality of life were observed in 3 out of 19 domains assessed in the active group. A re-intervention rate of 26.7% was seen in both groups.

Conclusions

These findings suggest that extracorporeal shockwave therapy is effective in improving walking distances at 12 months. Although this study provides important pilot data, a larger study is needed to corroborate these findings and to investigate the actions of this treatment.

ISRCTN: NCT02652078.

Keywords

Extracorporeal shockwave therapy intermittent claudication peripheral arterial disease randomised controlled trial

Get full access to this article

View all access options for this article.

References

Norgren

Hiatt

Dormandy

et al . Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45: S5–S67.

Breek

de Vries

van Heck

et al . Assessment of disease impact in patients with intermittent claudication: discrepancy between health status and quality of life. J Vasc Surg 2005; 41: 443–450.

Hobbs

and Bradbury

AW.

Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach. Eur J Vasc Endovasc Surg 2003; 26: 341–347.

Berger

and Hiatt

WR.

Medical therapy in peripheral artery disease. Circulation 2012; 126: 491–500.

National Institute for Health and Clinical Excellence. Lower limb peripheral arterial disease: diagnosis and management. NICE Clinical Guideline 147, www.nice.org.uk/guidance/cg147?unlid=15392835020159593813 (2012, accessed 10 November 2016).

Gardner

and Poehlman

ET.

Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995; 274: 975–980.

Mazari

Khan

Samuel

et al . Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease. Br J Surg 2017; 104: 76–83.

Harwood

Smith

Cayton

et al . A systematic review of the uptake and adherence rates to supervised exercise programs in patients with intermittent claudication. Ann Vasc Surg 2016; 34: 280–289.

Harwood

Smith

Broadbent

et al . Access to supervised exercise services for peripheral vascular disease patients. Bull R Coll Surg Engl 2017; 99: 207–211.

10.

McAteer

and Evan

AP.

The acute and long-term adverse effects of shock wave lithotripsy. Semin Nephrol 2008; 28: 200–213.

11.

Schaden

Thiele

Kölpl

et al . Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study. J Surg Res 2007; 143: 1–12.

12.

Jiang

Chen

et al . Extracorporeal shock wave treatment in nonunions of long bone fractures. Int Orthop 2009; 33: 789–793.

13.

Wang

Chen

et al . Treatment of nonunions of long bone fractures with shock waves. Clin Orthop 2001; 95–101.

14.

Cayton

Harwood

Smith

et al . A systematic review of extracorporeal shockwave therapy as a novel treatment for intermittent claudication. Ann Vasc Surg 2016; 35: 226–233.

15.

Harwood

Green

Cayton

et al . A feasibility double-blind randomized placebo-controlled trial of extracorporeal shockwave therapy as a novel treatment for intermittent claudication. J Vasc Surg 2018; 67: 514–521.

16.

Cayton

Harwood

Smith

et al . Extracorporeal shockwave therapy for the treatment of lower limb intermittent claudication: study protocol for a randomised controlled trial (the SHOCKWAVE 1 trial). Trials 2017; 18: 104.

17.

Serizawa

Ito

Kawamura

et al . Extracorporeal shock wave therapy improves the walking ability of patients with peripheral artery disease and intermittent claudication. Circ J 2012; 76: 1486–1493.

18.

Lane

and Lip

GYH.

Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2013; 12: CD003075.

19.

Parmenter

Raymond

and Singh

MAF.

The effect of exercise on fitness and performance-based tests of function in intermittent claudication: a systematic review. Sports Med 2013; 43: 513–524.

20.

Gupta

and Elkins

MR.

Supervised walking training improves maximum and pain-free walking distances in people with intermittent claudication. Br J Sports Med 2014; 48: 1130–1132.

21.

Al-Qaisi

Nott

King

et al . Ankle brachial pressure index (ABPI): an update for practitioners. Vasc Health Risk Manag 2009; 5: 833–841.

22.

Harwood

Cayton

Sarvanandan

et al . A review of the potential local mechanisms by which exercise improves functional outcomes in intermittent claudication. Ann Vasc Surg 2016; 30: 312–320.

23.

Lane

Harwood

Watson

et al . Exercise for intermittent claudication. Cochrane Database Syst Rev 2017; 12: CD000990.

24.

Parmenter

Raymond

and Fiatarone Singh

MA.

The effect of exercise on haemodynamics in intermittent claudication: a systematic review of randomized controlled trials. Sports Med Auckl NZ 2010; 40: 433–447.

25.

Kruidenier

Nicolaï

Rouwet

et al . Additional supervised exercise therapy after a percutaneous vascular intervention for peripheral arterial disease: a randomized clinical trial. J Vasc Interv Radiol 2011; 22: 961–968.

26.

Fakhry

Rouwet

den Hoed

et al . Long‐term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial. Br J Surg 2013; 100: 1164–1171.

27.

Gommans

LNM

Fokkenrood

HJP

van Dalen

HCW

et al . Safety of supervised exercise therapy in patients with intermittent claudication. J Vasc Surg 2015; 61: 512–518.e2.

28.

Axisa

Fishwick

Bolia

et al . Complications following peripheral angioplasty. Ann R Coll Surg Engl 2002; 84: 39–42.

29.

Raza

Harwood

Totty

et al . Extracorporeal shockwave therapy for peripheral arterial disease: a review of the potential mechanisms of action. Ann Vasc Surg 2017; 45: 294–298.

30.

Aicher

Heeschen

Sasaki

et al . Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation 2006; 114: 2823–2830.

31.

Holfeld

Tepeköylü

Blunder

et al . Low energy shock wave therapy induces angiogenesis in acute hind-limb ischemia via VEGF receptor 2 phosphorylation. PloS One 2014; 9: e103982.

32.

Tepeköylü

Wang

Kozaryn

et al . Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34-positive endothelial cells in a hindlimb ischemia model: implications for angiogenesis and vasculogenesis. J Thorac Cardiovasc Surg 2013; 146: 971–978.

33.

Lau

and Wang

DA.

Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther 2011; 11: 189–197.

34.

Yoder

MC.

Human endothelial progenitor cells. Cold Spring Harb Perspect Med 2012; 2: a006692.

35.

Popplewell

and Bradbury

AW.

Why do health systems not fund supervised exercise programmes for intermittent claudication?

Eur J Vasc Endovasc Surg 2014; 48: 608–610.

36.

Fowkes

Housley

Cawood

et al . Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384–392.